Repros Therapeutics Inc.
RPRX
RPRX was delisted on the 31st of January, 2018.
58 hedge funds and large institutions have $104M invested in Repros Therapeutics Inc. in 2015 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 19 closing their positions.
276% more call options, than puts
Call options by funds: $12.7M | Put options by funds: $3.38M
3% less capital invested
Capital invested by funds: $106M → $104M (-$2.7M)
9% less funds holding
Funds holding: 64 → 58 (-6)
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.76M |
| 2 |
PA
Perceptive Advisors
New York
|
+$1.68M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$935K |
| 4 |
Barclays
London,
United Kingdom
|
+$876K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$455K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.01M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$1.24M |
| 3 |
Renaissance Technologies
New York
|
-$1.2M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.09M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$794K |
RPRX Hedge Fund Activity: Q3 2015 in Review
58 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q3 2015, worth a combined $104M — down 2.5% from $106M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of RPRX and 13 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 13 added.
The largest buyer was Morgan Stanley, adding an estimated $2.76M. The largest seller was Millennium Management, cutting an estimated $3.01M.
- 58 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q3 2015, down from 64 in Q2 2015.
- Funds reported $104M of Repros Therapeutics Inc. stock for Q3 2015, down 2.5% quarter-over-quarter.
- 13 funds opened new Repros Therapeutics Inc. positions in Q3 2015 and 19 closed out, a net change of -6 holders.
- The largest Repros Therapeutics Inc. buyer in Q3 2015 was Morgan Stanley, an estimated $2.76M added.
- The largest Repros Therapeutics Inc. seller in Q3 2015 was Millennium Management, an estimated $3.01M sold.
Based on aggregated 13F filings for Q3 2015.